2015 TCT late-breaking trials announced

160

The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at this years’ Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. (11–15 October, San Francisco, USA). The studies include ABSORB III, LEADERS FREE, and Sapien 3

According to a CRF press statement, from an unprecedented number of high-quality submissions, TCT has chosen 20 studies that will impact the care of patients and how physicians think about cardiovascular disease. The press statement reports that the studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease.The late-breaking clinical trials and first report investigations will be presented in the Main Arena on the Monday, Tuesday, Wednesday, and Thursday of the meeting. The studies are as follows:


Monday (12 October)

  • ABSORB III (A prospective randomized trial of an everolimus-eluting bioresorbable scaffold vs. an everolimus-eluting metallic stent in patients with coronary artery disease)
  • ABSORB China (A prospective randomized trial of an everolimus-eluting bioresorbable scaffold vs. an everolimus-eluting metallic stent in patients with coronary artery disease)
  • A prospective randomized trial of transradial vs transfemoral access in patients undergoing coronary angiography and intervention
  • ABSORB II (A prospective randomized trial of an everolimus-eluting bioresorbable scaffold vs. an everolimus-eluting metallic stent in patients with coronary artery disease—two-year outcomes)
  • BIOSOLVE II (Evaluation of a sirolimus-eluting bioresorbable metallic scaffold—six-month clinical, angiographic, and imaging outcomes)

Tuesday (13 October)

  • RIVER-PCI (A prospective, double-blind, placebo-controlled randomized trial of ranolazine in patients with incomplete revascularization after coronary intervention)
  • EXPLORE (A Prospective randomized trial of chronic total occlusion intervention versus medical therapy after successful primary angioplasty in patients with ST-segment elevation myocardial infarction
  • TOTAL (A prospective randomized trial of thrombus aspiration in patients with ST-segment elevation myocardial infarction—one-year outcomes)
  • A prospective randomized trial of thrombus aspiration in patients with ST-segment elevation myocardial infarction presenting late after symptom onset
  • PLATFORM (Quality-of-life and economic outcomes of an FFR-CT diagnostic strategy in patients with suspected coronary artery disease)

 

Wednesday (14 October)

  • LEADERS FREE (A prospective, double-blind randomized trial of a polymer-free biolimus-eluting stent versus bare metal stents in patients with coronary artery disease at high risk for bleeding
  • TUXEDO (A prospective randomized trial of paclitaxel-eluting vs. everolimus-eluting stents in diabetic patients with coronary artery disease)
  • PANDA III (A prospective randomized trial of 2 sirolimus-eluting bioresorbable-polymer–based metallic stents with varying elution and absorption kinetics)
  • ISAR-DESIRE 4 (A prospective randomized trial of plaque modification with a scoring balloon during drug-coated balloon treatment of coronary in-stent restenosis)
  • IN.PACT SFA (A prospective randomized trial of a drug-coated balloon for femoropopliteal lesions—two-year outcomes)

 

Thursday (15 October)

  • BRAVO 3 (A prospective randomized Ttrial of bivalirudin versus heparin in patients undergoing transcatheter aortic valve replacement)
  • SAPIEN 3 (Evaluation of a balloon-expandable transcatheter aortic valve in high-risk and inoperable patients with aortic stenosis—one-year outcomes)
  • RESPECT (A prospective randomized trial of PFO closure in patients with cryptogenic stroke—long-term results)
  • Evaluation of initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis
  • PARTNER II Valve-in-Valve Registry (Evaluation of a balloon-expandable transcatheter aortic valve in patients with failed bioprosthetic surgical aortic valves)
(Visited 13 times, 1 visits today)